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Abstract
Calanquinone A (1) was isolated from an EtOAc-soluble extract of Calanthe arisanensis through
bioassay-guided fractionation. Its structure was identified by spectroscopic methods. Compound 1
showed potent cytotoxicity (EC50 < 0.5 µg/mL) against lung (A549), prostate (PC-3 and DU145),
colon (HCT-8), breast (MCF7), nasopharyngeal (KB), and vincristine-resistant nasopharyngeal (KB-
VIN) cancer cell lines, and interestingly, showed an improved drug resistance profile compared to
paclitaxel. The total synthesis of 1 was also achieved and reported herein.
The Calanthe genus in the Orchidaceae family contains terrestrial perennial herbs that are
widely distributed from tropical Africa and Madagascar to tropical and subtropical Asia, China,
Japan, southward through Malaysia and Indonesia to the Pacific islands and Australia. This
genus includes more than 150 species, but only nineteen are found in Taiwan. Among them
Calanthe arisanensis Hayata is endemic to Taiwan and grows in forests from 1000 to 2000 m
throughout the island.1
A phytochemical study of this plant has not been reported to date. In cytotoxicity screening of
extracts of Formosan plants, an EtOAc extract of C. arisanensis was found to be active against
various human cancer cell lines with IC50< 20 µg/mL. Bioassay-directed chromatographic
fractionation of this extract produced a new phenanthraquinone calanquinone A (1). Compound
1 showed significant in vitro cytotoxic activicity against seven human cancer cell lines, as
described below.
The active MeOH extract (225 g) of dry roots of C. arisanensis (5.42 kg) was partitioned
between EtOAc and water (1:1, v/v). Further fractionation of the active EtOAc extract (32.7
g) by repeated liquid chromatography on silica gel gave calanquinone A (1). HRESIMS of 1
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showed a [M-H]− ion at m/z 313.0705 (C17H14O6 -H), indicating 11 degrees of unsaturation.
The IR spectrum showed absorptions for hydroxyl (3348 cm−1), carbonyl (1642 cm−1), and
aromatic ring (1626, 1514, 1460, 1411, and 844 cm−1) functional groups. UV absorptions at
242, 308, and 426 nm also indicated an aromatic system. Seventeen carbon signals, including
three methoxy, four methine, and ten quaternary carbons, were observed in the NMR spectra
of 1 (Table 1). Among the ten quaternary carbons, two were identified as carbonyl carbons on
the basis of chemical shifts δC 184.7 and 186.2. Therefore, the data supported the presence of
two carbonyls, six olefins, and three ring moieties to fulfill the 11 degrees of unsaturation, and
1 was postulated to be an phenanthrenedione or anthrenedione.2 1D NMR and HSQC data
indicated the presence of three methoxy groups at δH 3.96, 4.01, and 4.02 (δC 57.1, 56.2, and
61.0), one pair of ortho-coupled aromatic protons at δH 8.05 (d, J=8.7 Hz, δC 137.1) and 8.10
(d, J=8.7 Hz, δC 122.0), and two olefinic protons at δH 6.15 (s, δC 107.4) and 6.86 (s, δC 101.4).
In the HMBC spectra, the olefinic proton at δH 6.86 exhibited 2J interactions with a carbon at
δC 155.2 (C-7), as well as 3J interactions with carbons at δC 118.7 (C-4b), 140.4 (C-6), and
137.1 (C-9). The other olefinic proton at δH 6.15 exhibited 2J interactions with a carbon at
δC 161.7 (C-3), as well as 3J interactions with carbons at δC 186.2 (C-4) and 133.0 (C-10a).
Locations of methoxy groups at C-3, C-6, and C-7 were confirmed by the following NOESY
correlations: δH 6.15 (H-2)/3.96 (3-OMe), δH 6.86 (H-8)/4.01 (7-OMe) and 8.05 (H-9), δH 4.01
(7-OMe)/4.02 (6-OMe), and δH 8.05 (H-9)/8.10 (H-10). Thus, compound 1 was identified as
5-hydroxy-3,6,7-trimethoxy-1,4-phenanthrenequinone and has been named as calanquinone
A (1).
Compound 1 is related in structure to other naturally occurring phenanthrenequinones,
including the des-oxy analog sphenone (lacking the C-5 OH group),3 cymbinodin A (lacking
the two methoxy groups at C-6 and C-7),4 and annoquinone A (lacking any substituents on
ring C).5,6 In prior studies, sphenone and annoquinone A showed cytotoxic activity against
the KB cell line (reported EC50 2.73 and 1.65 µg/mL, respectively).
Compound 1 exhibited potent cytotoxicity (EC50 0.03–0.45 µg/mL) against human lung
(A549), prostate (PC-3 and DU145), colon (HCT-8), breast (MCF7), nasopharyngeal (KB),
and vincristine-resistant nasopharyngeal (KB-VIN) cancer cell lines. Paclitaxel was used as a
positive control (data shown in Table 2). Interestingly, 1 exhibited comparble potency against
both KB and its drug-resistant KB-VIN subline, and thus, showed an improved drug resistance
profile compared to paclitaxel. The cytotoxic values demonstrate the strong potential of 1 as
a promising lead compound and C. arisanensis as a promising plant source of new agents for
cancer chemotherapy.
In order to make sufficient quantities of 1 for extensive biological evaluation, we modified the
synthetic procedure of Kraus and co-workers7,8 (Scheme 1) to synthesize 1. As shown in
Scheme 2, we prepared 2-methoxy-5-carboxylic acid methyl ester-1,4-quinone (4)9 by AgO
oxidation of the methyl ester (3) of commercially available 2,4,5-trimethoxybenzoic acid (2).
Compound 4 was coupled with 3,4,5-trimethoxytoluene in the presence of 1 equiv. of
trifluoroacetic acid to produce quinone 5, although Kraus reported the production of
hydroquinone 10 under these reaction conditions (Scheme 1). The quinone skeleton of 5 was
confirmed from 13C-NMR data, which showed two carbonyl groups at 180.6 and 183.6 ppm.
In addition, reaction of 5 with Me2SO4 did not give a methoxylated product (i.e., 11 in Scheme
1). We attempted to reduce 5 with Na2S2O4 to obtain the corresponding hydroquinone, which
could be transformed to the Kraus type of intermediate 11 (R = OMe) after methylation. Despite
extending the reaction time and adding more reducing agent, only starting material was
recovered.
Therefore, 5 was reduced with LAH (THF, reflux, 1 h) to alcohol, which was oxidized
selectively to aldehyde 6 with activated MnO2 (toluene, 110 °C, overnight) (Scheme 2). After
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an unsuccessful attempt to obtain the phenanthraquinone 9 directly from 6 using P4-tBu,
quinone 6 was first reduced to the hydroquinone using aq. Na2S2O4 (CH2Cl2, rt., overnight),
10 and then methylated with Me2SO4 in the presence of K2CO3(acetone, 60 °C, 1.5 h) to give
the desired compound 7 (Scheme 2). Cyclization of 7 with P4-t Bu (benzene, 100 °C, 63 h)
gave 8, which was oxidized with AgO (6N HNO3, acetone, 50 °C, 2–3 min) to
phenanthraquinone 9. Compound 9 was converted to calanquinone A (1) by selective
demethylation with TMSI in CH2Cl2 at r.t. (Scheme 2).
Synthesized 1 and intermediates 5–9 were screened in an in vitro cytotoxicity assay (data shown
in Table 3). Compound 1 exhibited the highest potency (EC50 0.15–0.75 µg/mL) against all
seven tested cancer cell lines. The remaining compounds showed no (6–8) or only weak (5 and
9) activity. Clearly, the potency of 1 merits further study and our synthetic route can efficiently
produce sufficient quantities of 1 for future extensive biological evaluation and SAR
investigation.
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Structure of calanquinone A (1).
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Synthetic procedure of Kraus.
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Our total synthesis of calanquinone A (1).
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Table 1
NMR data of calanquinone A (1)a
Proton 13C (δC)
1H (δH) HMBC (
13C no) NOESY (1H no)
1 184.7








8 101.4 6.86 s 4b, 6, 7, 9 9, C7-OCH3
8a 135.1
9 137.1 8.05 d (8.7) 4b, 8, 10a 8, 10
10 122.0 8.10 d (8.7) 1, 4a, 8a 9
10a 133.0
−OCH3 C3-OCH3 57.1 C3-OCH3 3.96 s 3 2
C6-OCH3 61.0 C6-OCH3 4.02 s 6 C7-OCH3
C7-OCH3 56.2 C7-OCH3 4.02 s 7 8, C6-OCH3
C5-OH 10.73
a
Measured in CDCl3 (300 and 500 MHz, δ in ppm, J in Hz).
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